Linde India (523457) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
11 Aug, 2026Executive summary
Unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 were approved by the Board on 11 August 2026.
Appointment of Mr. Vikash Dokania as Chief Financial Officer effective 15 September 2026.
Financial highlights
Standalone revenue from operations for Q1 FY27 was ₹6,943.63 million, up from ₹5,710.80 million in Q1 FY26.
Standalone profit after tax for Q1 FY27 was ₹1,030.33 million, compared to ₹1,050.73 million in Q1 FY26.
Consolidated revenue from operations for Q1 FY27 was ₹6,943.63 million, up from ₹5,710.80 million in Q1 FY26.
Consolidated profit after tax for Q1 FY27 was ₹1,045.94 million, compared to ₹1,071.90 million in Q1 FY26.
Basic and diluted EPS (standalone) for Q1 FY27 was ₹12.08, compared to ₹12.32 in Q1 FY26.
Outlook and guidance
Management regularly evaluates business and regulatory risks, with uncertainties around the outcomes of ongoing legal and regulatory proceedings.
Latest events from Linde India
- Record EBITDA and debt reduction, but divestment drove reported profit amid COVID-19 uncertainty.523457
Q4 2019 - Underlying gases growth and lower interest costs cushioned a pandemic-hit FY2020.523457
Q4 2020 - FY21 rebounded strongly, though reported profit included a major land-sale gain.523457
Q4 2021 - Strong growth, a debt-free balance sheet and a Rs 14,200 million PED order book.523457
Q4 22/23 - Revenue and EBITDA grew, led by Gases, amid unresolved related-party proceedings.523457
Q4 23/24 - Strong financial results and dividend, but regulatory/legal uncertainties led to a qualified audit opinion.523457
Q4 25/26 - Q3 FY26 profit after tax rose to ₹1,933.25 million amid ongoing regulatory uncertainties.523457
Q3 25/26 - Q2 FY26 saw strong revenue and profit growth, but regulatory risks remain elevated.523457
Q2 25/26 - Quarterly profit and revenue declined year-over-year amid ongoing SEBI regulatory scrutiny.523457
Q3 24/25